Company intelligence / Profile preview
Artan Bio
United Statesartan.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Artan Bio is developing engineered tRNA suppressor systems to correct premature stop codon mutations implicated in rare genetic and aging-related diseases. The platform has demonstrated proof of concept in cellular models and is entering preclinical animal validation[1][2].
- Therapeutic areas
- OtherRare Diseases
- Modalities
- Gene therapyEngineered tRNA suppressor therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
VitaDAOSyenex VivoCell
Beyond the preview
Go deeper on Artan Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Artan Bio.